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Lymphomatoid granulomatosis (LYG) in renal transplant recipients is rare multisystemic angiocentric lymphoproliferative disor-
der with signiﬁcant malignant potential. Here, we describe LYG in a 70-year-old renal allograft recipient who, 4 years after trans-
plantation,ontacrolimusandmycophenolatemofetilandprednisonemaintenanceimmunosuppression,complainedoflow-grade
fever, persistent headache and gait disturbance. The MRI of the brain revealed diﬀuse periventricular cerebral and cerebellar
contrast-enhanced lesions. The CT scan of the thorax showed multiple pulmonary nodular opacities in both lung ﬁelds. The
patient was diagnosed LYG based on the cerebral biopsy showing perivascular inﬁltration of CD20-positive B-lymphocytes with
granulomatous lesions and immunoﬂuorescence staining with anti-EBV antibodies. With careful reduction of the immunossup-
pression combined with the use ofrituximab, our patient showed a complete disappearance of LYG, and she is clinicallywell more
than 4 years after the diagnosis, with good kidney function. No recurrence has been observed by radiological imaging until now.
This is the ﬁrst report of a durable (>4 years) complete remission of LYG after treatment with rituximab in renal transplantation.
1.Introduction
Posttransplant lymphoproliferative diseases (PTLD) are rec-
ognized as a main complication following solid organ trans-
plantation. They generally occur in the 1st posttransplant
year and may be triggered by Epstein-Barr virus (EBV)
infection. Lymphomatoid granulomatosis (LYG) is a rarer
disease, characterized by angiocentric and necrotising lym-
phoproliferation [1, 2] Its low prevalence and its lethal
outcomedidnotallowtowellestablishanobvioustreatment.
We report here a case of a patient who had developed LYG
with cerebraland pulmonary localization, treated successful-
ly with rituximab. To our knowledge, this is the ﬁrst case
reported in renal transplantation.
2.CaseReport
A 70-year-old woman, with renal failure secondary to
chronic glomerulonephritis, had her 1st renal transplanta-
tion in 1993, after being on haemodialysis for 54 months.
She was treated with an immunosuppressive regimen
including lymphoglobuline, corticosteroids, azathioprine,
and ciclosporine. Next, a transplantectomy was realized on
day 15 as she developed Candida glabrata septicaemia. Her
second transplantation was performed in 2001. The initial
immunosuppressive treatment consisted of Thymoglobu-
line, corticosteroids,mycophenolatemofetil (MMF)and tac-
rolimus. Her serological tests for cytomegalovirus (CMV)
andEBVwerepositiveindicatingpreviousinfection,whereas
that of toxoplasma was negative (negative IgG and IgM).
Donor IgG of CMV and EBV were positive, in contrast,
IgG and IgM of toxoplasma were negative. During the ﬁrst
posttransplant year, the patient presented CMV invasive
infection with CMV-pneumonia; she was treated by IV
Ganciclovir. After this episode, the patient was stable for
almost 2 years. During the 4th year posttransplantation,
she had presented multiple episodes of bronchopulmonary
infection. Chest X-ray exams and CT scan did not show
any abnormality. 54 months after transplantation, she had
presented low-grade fever 38◦C, posterior and temporal2 Journal of Transplantation
headache, progressive gait, and balance disorders, then a
persistent cough. At this moment, her immunosuppressive
treatment associated MMF(1,5g/d), tacrolimus(1,5mg/d),
and prednisone(5mg/d). The laboratory results revealed no
elevated inﬂammatory markers, normal hepatic enzymes,
and normal LDH; creatinine clearance according to MDRD
formula was 42mL/mn/1,73m2 and tacrolimus trough level
was 5µg/l.
Analyses for EBV and CMV viruses by plasmatic PCR
were negative. A lumbarpuncturewas performed; it revealed
8 cellular elements/mm3. The bacteriological, virological,
mycological, and parasitological tests of the cerebrospinal
ﬂuid were all negative. The CT scan of the head without
contrast injection was normal. The MRI performed 3 days
later detected diﬀuse periventricular cerebral and cerebellar
contrast-enhanced lesions (hypersignal Flair) (Figure 1). In
view of these ﬁndings, the diagnosis of cerebral toxoplas-
mosis was considered. A reduction of immunosuppression
(MMF 1g/d) was performed and an antitoxoplasma treat-
ment (malocide+sulphadiazine) was started. One month
later, due to the absence of any clinical improvement with
the treatment, a stereotactic cerebral biopsy was carried out.
Thehistologicalstudy(Figure 2)showedaheterogeneous
necrotising lesion, with cellular remnants, granulomatous
clusters of giant cells, with circumvented nuclei and well
visible nucleoli, which looked like lymphoplasmocyte cells.
The cells created dense castings on the meninges and
were inﬁltrating the wall of several vessels. The immuno-
histochemical study showed granulomatous cells stained
by antibodies (ab) anti-CD68 (macrophages), anti-CD20
(B cells), and anti-CD30. The reaction to anti-EBV ab
(anti-LMP1) was positive; conversely, the reaction to anti-
toxoplasma ab was negative. In view of these results,
we concluded a grade III lymphomatoid granulomatosis
according to LIPFORD classiﬁcation [3, 4]. A complete
workup including chest and abdominal CT was carried out.
The CT scan of the thorax showed 6 pulmonary nodules of
tissular density in the left lung and one pulmonary nodule
in the right lung (Figure 3(a)). The CT of the abdomen was
free. The bronchial endoscopy revealed purulent secretions
with severe inﬂammatory reaction. Bronchoalveolar lavage
was negative for Koch’s bacillus. The histological study
showed unsteadily scraped bronchial mucous membrane.
The subjacent chorion was composed of an inﬂammatory
polymorphic inﬁltrate, rich in polynuclear eosinophils with
small growing granulomas. The diagnosis of grade III LYG
with pulmonary and cerebral localization was considered.
So, the immunosuppression was again minimized. MMF
was discontinued; tacrolimus was reduced to 1mg/d, to
achieve trough levels around 3ng/mL, whereas prednisone
was increased to 0.5mg/kg/d.
Two months following immunosuppression reduction,
thelesions were persistently unchanged. Atreatment by anti-
CD20 antibodies was then initiated (Rituximab: 375mg/m2
weekly for 4 weeks). Markedly, after the ﬁrst two doses, a
signiﬁcant clinical improvement was noted. The tolerance of
rituximab was good. Six months later, the patient reported
a complete disappearance of headache and a signiﬁcant
regression of gait disorders. Two years later (December
2007), there was no clinical sign of recurrence, the renal
function was stable, and the brain MRI showed the persis-
tence of hypersignals and infarction zones remnants. The
thoracic CT scan showed only a single nodule (Figure 3(b)).
The immunosuppressive treatment consisted of tacrolimus
1mg/d and prednisone 0.2mg/kg/d.
The last thoracic and brain CT scans (February 2010)
showed a complete disappearance of the pulmonary and
cerebral lesions. Laboratory results revealed creatinine level
1.1mg/dL (101µmol/L), negative proteinuria, normal LDH
level, and negative EBV plasmatic PCR. Immunopheno-
typing of blood lymphocytes revealed low CD19 count
(10/mm3).
3.Discussion
This paperhighlights the diagnostic and therapeuticdiﬃcul-
ties of LYG. Our patient presented many risk factors of this
disease including: age, immunosuppression, administration
of antilymphocyte sera for her two renal transplants, and the
reactivation ofCMV. The clinical presentation demonstrated
the heterogenecity and the abundance of the symptoms. It
should be noted a clinicoradiological delay for the diagnosis
ofpulmonarylesions. Ourtherapeuticapproach wassequen-
tial, initially by a reduction in the immunosuppression, then
rituximab was introduced.
3.1. Frequency. LYG is a rare disorder belonging to the
group of type B lymphoproliferative diseases. It aﬀects males
> females (2 men for 1 woman) and aﬀects primarily
immunocompromised patients. The peaks of frequency
concern 3rd and 6th decades [5, 6]. Patients presenting LYG
have 10 to 60% risk to develop large B cells lymphoma.
LYG is a serious disorder with a median survival of 2 years
in the general population. The main cause of death is the
progression of pulmonary lesions [7].
In renal transplantation, the literature reported 6 cases
among which 3 cases were diagnosed postmortem and 3
other cases with good outcome (one case after a reduction
inimmunosuppression, 2 casesafter chemotherapy) [1, 2,8–
11].
3.2. Clinical Features. LYG can aﬀect all organs and may
simulate a systemic disease. Clinical presentation varies
according to the localization of granulomatous lesions [12].
Lung involvement is present in approximately 90% of
cases [13]. Cutaneous lesions (25–50% of cases) were also
reported, as well as central nervous system lesions (25–35%
of cases) with multiple and focal localizations [14]. Other
organs can be aﬀected: the kidneys (20 30%), the liver (20
30%), and, less frequently, gastrointestinal tract [8, 12].
3.3. Diagnostic Diﬃculty. Due to its rarity, its various clinical
presentations, and the absence of clinical, biological, or
radiological speciﬁcity, the recognition of LYG is usually
complex. This explains the delay of the diagnosis which can
go up to 3 to 6 months after the beginning of the symptoms.Journal of Transplantation 3
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Figure 1: Cerebral MRI: (a) coronal view T1 with gadolinium injection: left cerebellar nodular lesion with central necrotic zone and
peripheral contrast enhancement. (b) Coronal view T1 without gadolinium injection: periventricular localization of multiple cerebral
hypersignal nodular lesions.
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Figure2:Cerebellar biopsy:(a)nodulargranulomatouslesionwithmononuclearcells(Hematein-eosin×40).(b)Atypicalcellswithmitosis
(∗) (Hematein-eosin×40). (c) Staining with anti-CD20 (×40): atypical cells are stained. (d) Staining with anti-EBV-LMP1 (×40): a lot of
cells are stained.
Unfortunately, the diagnosis is realised by autopsy in many
cases [8–10].
3.4. Complementary Examinations. Blood analyses, lumbar
puncture examination, and imaging assessments are not
speciﬁc. Radiological examinations can localize the lesions,
but often with a clinicoradiological lag [1]. Brain MRI is
the examination of choice for cerebral lesions. The lesions
are often multiple, with T2 hyperintense signal. The most
characteristic aspect is the punctiform or linear pattern of
enhancement [14]. After treatment, an enhanced T2 can
persist; however, a complete disappearance of the cortical
infarction zones can be reached, as happened in our patient.
The thoracic CT scan demonstrates multifocal inﬁltration in
the lungs, predominating the lower lobes, with variable radi-
ological aspects: reticulonodular alveolar opacities, pleurisy,
or nodules [15, 16].
3.5. Histopathological Examination. Three-tiered grading
system (I, II, and III) have been proposed by Lipford et
al. for LYG on the basis of cellular atypia and degree of
inﬂammatory background. This classiﬁcation predicts the4 Journal of Transplantation
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Figure3:Pulmonarylocalisationoflymphomatoidgranulomatosis.TransverseCTview,withcontrastinjectioninparenchymatous window
showingnodularlesionstakingcontrast.(a)Atinitialdiagnosis.(b)2yearsafterreductionintheimmunosuppressionandrutiximabtherapy.
response to treatment and the survival [3, 17]. Nevertheless,
it is important to note the diﬃculty of the histopathological
diagnosis, as the presence of wide zones of inﬂammation and
necrosis may suggest an infectious origin (such as toxoplas-
mosis) rather than LYG.
Our patient was grade III. The histological analysis
showed an angiodestructive polymorphous lymphoid inﬁl-
trate. The cells were overwhelmed within important necro-
tising zones and altered inﬂammatory residues. They were
gatheredingranulomatousclusterswithlymphoidabnormal
cells of type B and lymphoplasmocyte cells. There was an in-
ﬁltration of the vascular wall with intravascular thrombi.
The immunophenotyping illustrated a positive stain by anti-
CD20+ ab (B cells), anti-CD68+ ab (macrophages), anti-
CD30 ab, and EBV-LMP1+ ab revealing EBV infection.
3.6. Risk Factors. EBV is the principal trigger factor of
lymphoproliferation (especially in cases of donor EBV+/
recipient EBV−). EBV viral load is considered to play a
key role in mediating the disease process [4]. Infection with
CMV, which occurred in our patient, may also contribute
in lymphoproliferation development. The over-immuno-
suppression is supposed to be responsible, in particular
the cumulative doses of antilymphocyte sera. Moreover, the
impact of other factors as age and cigarette smoking have
been also reported [4, 18].
3.7. Management. There are scanty data in the literature
concerning the management of LYG. In our patient, we
considered that it might be beneﬁcial to reduce calcineurin
inhibitors by 50% and withdraw antiproliferative medica-
tions (mycophenolate or azathioprine) based on data previ-
ously reported in overall PTLD [1, 19].
An early trial showed improved survival with therapy
comprising corticosteroids and cyclophosphamide,but mor-
talityofLYGremainedveryhigh[20].Combinedchemother-
apy using CHOP protocol (cyclophosphamide, doxoru-
bicine, vincristine, and prednisone) was also proposed [5].
More recently, few reports have tried a targeted therapy
with the anti-CD20 antibody rituximab with or without tra-
ditional combined chemotherapy. To date, a total of 12 cases
were published in the literature. The responses were success-
ful in 9 cases [6, 13, 21–27], or ineﬀective in 3 cases [28–
30];however,none ofthose series concernedrenal transplant
patients.
4.Conclusion
LYG diagnosis is complex because of the diversity of its
clinical presentation, the nonspeciﬁc imaging aspects, and
the diﬃculty of histopathological reading. To be successfully
treated, this malignant disorder requires an early manage-
ment.Ourreport showedthatrituximabcouldbeconsidered
avaluableoptionfor thetreatment ofLYG inrenal transplant
patients.
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